Program plans to enroll approximately 17,000 participants across three global studies Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the initiation of the company's Phase 3
A readjudication of mortality data from the FOURIER trial by outside researchers concludes CV death was higher with evolocumab than originally reported. But FOURIER trialists stand by their conclusions.